Nature Reviews Drug Discovery Paper on Lead Generation Models Co-Authored by LCGC Founder Melvin Reichman, PhD - January 1, 2014

(LCGC) founder, president and CSO Melvin Reichman, PhD has co-written a paper for Nature Reviews Drug Discovery (NRDD), entitled “Opening the lead generation toolbox,” regarding the challenges of public/private partnering and pharmaceutical collaborations in early-stage drug discovery.

The search for effective new drugs can be long, unproductive, and quite expensive. To cut costs, large pharmas have been reducing their research efforts and looking elsewhere for novel targets or strong leads. That searching has pointed to academia, where there is a push towards translational research using high throughput screening (HTS), and to other pharmas with complementary assets, including lead-generating chemical libraries. However, barriers exist to these types of collaborations. Common points of contention are issues involving confidentiality and ownership of intellectual property, knowledge pertaining to lead compounds, and how the details are handled from a business development perspective.

In the NRDD review, Dr. Reichman and his colleague Dr. Peter B. Simpson, Director of Screening Sciences at AstraZeneca, UK, discuss several current collaborative models that address the sensitive issues of knowledge sharing, intellectual property (IP) rights, and commercial pursuits. Of note is the open innovation concept Double-Blinded Drug Discovery (DBD2)®, conceived and developed by Dr. Reichman. DBD2 was designed to fully protect the IP of both parties while fostering cooperation to accelerate the process of targeted drug discovery and validation.

“Early-stage drug discovery is evolving into an endeavor in which scientific research communities in both the public and private sectors are finding new ways of achieving 'IP comfort' while sharing knowledge, expertise and resources,” explains Dr. Reichman. “Unlocking those tools across various academic and business sectors has the potential to enable the scientific community to more rapidly validate innovative targets as druggable and reinvigorate translational research.”

In addition to being the founder, president and CSO of LCGC, Dr. Reichman has recently been appointed President-Elect of the International Chemical Biology Society for the year 2014-2015. He has a PhD in Neuroscience, and has held many leadership positions including with GD Searle, Berlex Biosciences, Ligand Pharmaceuticals, and DuPont. With over 20 years in the industry, Dr. Reichman has been an invited expert on all aspects of drug discovery at more than 50 events worldwide. He has authored numerous peer-reviewed publications, has been a reviewer for many NIH study sections, and is an editor for several leading journals. A seasoned scientific advisor, Dr. Reichman lends his expertise to several start-up companies in the area of pharmaceutical research and development.

Melvin Reichman, PhD, Founder of LCGC, Named President-Elect of the International Chemical Biology Society - November 1, 2013

ICBS LogoThe International Chemical Biology Society (ICBS) has named Melvin Reichman, PhD President-Elect of the organization for the year 2014-2015. As President-Elect, Dr. Reichman will lead ICBS in expanding the mission of the Society and co-chair the 2015 Annual Meeting.

"It has been my privilege to help form and contribute to the growth of ICBS," comments Dr. Reichman. "My focus as President will be to encourage expansion of Society membership from international scientific communities and recruit active participation of scientists from chemical biology disciplines beyond pharmaceutical R&D. Partnerships with related societies and moving towards launching an ICBS journal will be exciting goals for us all.”

The International Chemical Biology Society was created in October of 2011 to serve an unmet need for an organization that would bring together researchers across disciplines and business sectors to germinate and nurture ideas that merge biology and chemistry. Dr. Reichman is also chairman of the board and an ICBS organizing committee member. He will assume the presidency of ICBS at the conclusion of their conference in November of 2014.

Dr. Reichman holds a PhD in Neuroscience from the University of Rochester Center for Brain Research, and has had a 20-year career in industry, holding leadership positions at GD Searle, Berlex Biosciences, Ligand Pharmaceuticals, and DuPont. He has been an invited expert on all aspects of drug discovery at more than 50 events worldwide. He has authored many peer-reviewed publications, has been a reviewer for many NIH study sections, and is an editor for several leading journals. A seasoned scientific advisor, Dr. Reichman lends his expertise to several start-up companies in the area of pharmaceutical research and development.

Currently, Dr. Reichman is the Founder, President and Chief Scientific Officer of (LCGC), a biotech company that utilizes a patented automated repository and screening technology for accelerating drug discovery, including new approaches to discover synergistic combination drugs.

About the International Chemical Biology Society

ICBS is an independent, nonprofit organization dedicated to promoting research and educational opportunities at the interface of chemistry and biology. ICBS provides an important international forum that brings together cross-disciplinary scientists from academia, nonprofit organizations, government, and industry to communicate new research and help translate the power of chemical biology to advance human health. For more information, see the ICBS website at

LCGC Achieves Second Research Milestone with Dynamis Therapeutics for Treatment of Diabetes Complications - August 19, 2013

(LCGC) announced they have achieved a second milestone in a research collaboration with Dynamis Therapeutics, Inc. for discovery of new drug leads. The program at LCGC continues to focus on the fructosamine-3-kinase (FN3K) enzyme as a target for developing new treatments for complications of both Type I and Type II diabetes.

"We are delighted to continue working with the Dynamis team on the FN3K enzyme which is a highly innovative target for drug development in diabetes," notes Melvin Reichman, PhD, President and Founder of LCGC. "Our work holds promise for treating all of the most common complications of this increasingly common and debilitating disease." The company's proprietary technologies accelerated by 500% the screening of hundreds of thousands of diverse, drug-like molecules owned by LCGC in the definition of drug leads.

"This program is an ideal match between Dynamis' innovative technologies to treat diabetes complications and inflammation and LCGC's unique center of excellence in drug discovery support," states Annette M. Tobia, PhD, JD, Founder and CEO of Dynamis Therapeutics. "Our joint research will advance new therapies to the clinic for treating diabetic nephropathy and other diabetes complications."

Dynamis will continue to provide sponsored funding for LCGC to continue research in support of drug candidate optimization. The research was also supported by NIH grants from the National Institute of Diabetes and Digestive and Kidney Diseases (R43DK088407, SBIR) and the National Institute of Neurological Disorders and Stroke (R21NS061706).

About Dynamis Therapeutics, Inc.

Dynamis Therapeutics, Inc. (Jenkintown, PA) has proprietary drug candidates in preclinical development that selectively inhibit a novel signaling pathway catalyzed by the fructosamine-3-kinase (FN3K) enzyme. The FN3K enzyme initiates inflammation associated with hyperglycemia by triggering the formation of 3-deoxyglucosone (3DG). Research conducted by the company's founding scientists at Fox Chase Cancer Center, and confirmed by other researchers independently, indicates that prolonged hyperglycemia causes the accumulation of 3DG and is involved in the progression of diabetic complications. Evidence is emerging that this metabolic pathway is involved in the development of Alzheimer's disease. Annette M. Tobia, PhD, JD, is the Founder and CEO of Dynamis. She has raised over $10 million in equity financing, licensing fees, government grants and other instruments. For more information, please contact us through our webpage at

The Bill and Melinda Gates Foundation Awards LCGC a Grand Challenges Explorations Grant for Groundbreaking Research in Global Health and Development - November 1, 2012

(LCGC), a subsidiary of Lankenau Institute for Medical Research (LIMR), announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation. Melvin Reichman, PhD, President, CSO and Founder of LCGC, will pursue an innovative global health and development research project, titled "A Totally New Approach to Discover Malaria Combination Drugs".

"This Grand Challenges Explorations Award offers the project team an exciting opportunity to apply LCGC's unique ultra-high throughput screening technologies to discover novel, combination-drug leads against drug-resistant malaria," stated Dr. Reichman.

Grand Challenges Explorations (GCE) funds individuals worldwide who are taking innovative approaches to some of the world's toughest and persistent global health and development challenges. GCE invests in the early stages of bold ideas that have real potential to solve the problems people in the developing world face every day. Dr. Reichman's project is one of over 80 Grand Challenges Explorations Round 9 grants announced today by the Bill & Melinda Gates Foundation.

"Investments in innovative global health research are already paying off," said Chris Wilson, director of Global Health Discovery and Translational Sciences at the Bill & Melinda Gates Foundation. "We continue to be impressed by the novelty and innovative spirit of Grand Challenges Explorations projects and are enthusiastic about this exciting research. These investments hold real potential to yield new solutions to improve the health of millions of people in the developing world, and ensure that everyone has the chance to live a healthy productive life."

To receive funding, Dr. Reichman and other Grand Challenges Explorations Round 9 winners demonstrated in a two-page online application a creative idea in one of five critical global heath and development topic areas that included agriculture development, immunization and communications.

A Totally New Approach to Discover Malaria Combination Drugs

The (LCGC) will develop and validate a totally new, drug-screening paradigm for detecting drug synergy against Plasmodium falciparum using large compound sets of known antimalarials. We call our technology: 'ultra-High Throughput Screening for Synergy' (uHTSS). Our novel uHTSS approach will open new research corridors in polypharmacology and improve our understanding of the interplay between connected cell-signaling networks exploited by drug-resistant infection vectors. Achieving our objective will speed the discovery and development of more effective medicines that improve world health. Dr. Melvin Reichman, CSO of LCGC (USA), who is the Principal Investigator for the research, proposes to develop and validate uHTSS in collaboration with Professor Vicky Avery, PhD, Chief Investigator and Head at the Griffith University - Eskitis Institute for Cell and Molecular Therapies (Australia).

Dr. Reichman received his PhD in Neuroscience from the University of Rochester Medical School, Center for Brain Research. He has directed drug discovery research at several pharmas and biotech companies, including: GD Searle, Berlex Biosciences, Ligand Pharmaceuticals, Oncogene Sciences and DuPont Pharma. He founded LCGC in 2007 together with George Prendergast, PhD, CEO of LCGC and LIMR, to bridge a major divide between universities and pharmaceutical companies to accelerate the transfer and commercialization of biomedical technologies that improve human health.

About Grand Challenges Explorations

Grand Challenges Explorations is a US$100 million initiative funded by the Bill & Melinda Gates Foundation. Launched in 2008, over 700 people in 45 countries have received Grand Challenges Explorations grants. The grant program is open to anyone from any discipline and from any organization. The initiative uses an agile, accelerated grant-making process with short two-page online applications and no preliminary data required. Initial grants of US$100,000 are awarded two times a year. Successful projects have the opportunity to receive a follow-on grant of up to US$1 million.

About (LCGC)

's business model is a protected open-innovation framework called Double-Blinded Drug Discovery (DBD2)® that establishes a totally new, public-private partnering consortium. Our patented NanoTube Automated Repository System (NARS) can store 10-million compounds and rapidly retrieve them with a robot working in a room-size freezer on our campus. We provide pharma's vast medicinal libraries formatted in a new way that speeds new leads discovery by 500% for scientists in academia. A top-tier pharmaceutical company client and 13 international academic organizations have joined the DBD2 Consortium to date. LCGC is a for-profit biotech company wholly owned by Lankenau Institute for Medical Research (LIMR), an independent, nonprofit biomedical research center located in suburban Philadelphia on the campus of Lankenau Medical Center, Main Line Health.

LCGC Collaboration with Major Pharma Provides Large Chemical Collection for Drug Discovery
- June 27, 2011

(LCGC) announced today that it has entered into a partnership that will significantly enhance translational research and new leads discovery in academia by high throughput screening (HTS). A major pharma has provided a large, structurally representative snapshot (100,000 compounds) of their proprietary chemical collection to LCGC for approved distribution to university principal investigators. This will enable more effective probing and validation of the medicinal utility of innovative cell-signaling proteins and disease pathways.

The agreement with LCGC facilitates an entirely new approach, termed Double-Blinded Drug Discovery (DBD2)®, to identify and accelerate the discovery and commercialization of new drugs in fields with urgent patient need. Innovative robotic technology has been deployed that can store and rapidly retrieve up to 10 million individual chemicals. LCGC has also put into practice a more efficient HTS paradigm that enables principal investigators in academia to screen those chemicals 500% faster. These and other technologies, coupled with the new pharma collection, enable principal investigators at universities to more successfully discover new drug leads with the many assays resulting from their innovative biomedical investigations, without diluting their basic research mission. LCGC expedites information flow between the parties to further the development of new structure-activity relationships that might not occur otherwise. This new approach allows pharmaceutical companies to de-risk highly innovative targets much less expensively than by prematurely committing internal resources that could dilute drug-pipeline progression.

LCGC also provides unique opportunities for out-licensing and R&D funding to principal investigators desiring to pursue drug discovery and development with pharmas. The DBD2 consortium model has been endorsed by 13 academic organizations in the United States and internationally.


(LCGC) is a biotech company established in 2007 by Lankenau Institute for Medical Research (LIMR) to measurably accelerate pharmaceutical R&D in a new way. LCGC provides researchers access to large, pharmaceutical-grade compound libraries to validate innovative drug targets more successfully with a more efficient high-throughput screening technology. Our mission is to catalyze public-private partnerships in drug discovery research with an open-innovation framework called Double-Blinded Drug Discovery (DBD2)®, designed to protect and advance the research freedom and interests of both pharma and academia equally. For more information about LCGC, visit

About Lankenau Institute for Medical Research

Founded in 1927, the Lankenau Institute for Medical Research (LIMR) is an independent, nonprofit biomedical research center located in suburban Philadelphia on the campus of Lankenau Medical Center. Part of Main Line Health, LIMR is one of the few freestanding, hospital associated medical research centers in the United States. The faculty and staff at the Institute are dedicated to advancing an understanding of the causes of cancer, heart disease and diabetes. This information is used to help improve diagnosis and treatment of these diseases as well as find ways to prevent them. LIMR is also committed to extending the boundaries of human health and well-being through technology development and the training of the next generation of scientists and physicians. To learn about LIMR, visit

17th Annual SLAS/SBS Drug Discovery Meeting, Orlando, FL - March, 2011




National Institute of Diabetes & Digestive & Kidney Diseases SBIR Award Received by Dynamis Therapeutics to screen LCGC Library for Diabetes and Aging Inhibitors- July 27, 2010

Dynamis Therapeutics, Inc. received an NIH SBIR grant to discover inhibitors of a putative pathway contributing to diabetic complications which may also contribute to accelerated aging. The focus is on screening the LCGC library of chemical compounds for inhibitors of the enzyme fructosamine-3-kinase which plays a direct role in the formation of factors contributing to cellular aging and diabetic complications. More...

Small Business Innovation Research Award will Test and Develop New Products for Drug Discovery (2010)

LCGC, in collaboration with Istech, a company based in York, PA, received a Small Business Innovation Research (SBIR) Grant from the National Institutes of Health totaling $190,277.

LCGC is a biotech company that was created to fill a major gap in technology by providing access to large compound libraries that can be used to evaluate new drug targets using high-throughput screening. This is achieved using a state-of-the-art NanoTube Automated Retrival System (NARS), which was built by Istech and for which LIMR recently received exclusive worldwide license. The NARS machine has the capability to store over 10 million individual samples.

This SBIR award will allow Dr. Melvin Reichman, President of LCGC, and Marlin Yohn, President of Istech, to validate various compound management products in an effort to resolve bottlenecks that currently face scientists in the area of research materials management and drug discovery. The research and development team also consists of X-Act Technologies Inc. of Erie, PA, and REM Systems Inc. of Paoli, PA. They will use the NARS technologies they developed to find new ways to reduce the costs, increase the quality and productivity of drug discovery research, and allow for more reliable identification of new drugs. This will ultimately lead to improving health and could lead to additional unique applications in the field of forensics and genetic screening.

President of LCGC Elected to the Board of the Society for Biomolecular Sciences - January 21, 2010

Melvin Reichman, PhD, President and CSO of the LIMR Chemical Genomics Center (LCGC), was elected by members worldwide to serve a three-year term on the Board of Directors of the Society for Biomolecular Sciences (SBS). His service will begin April 12, 2010. SBS is the only non-profit international scientific society in the world that is dedicated to drug discovery and its associated disciplines. Dr. Reichman was an early founder of SBS while Head of Drug Discovery at Berlex/Schering AG. In his new role as director, he will provide vision and leadership for drug discovery sciences and practices as a delegate representing academic research communities, providing a unique perspective that includes an 18-year tenure in the pharmaceutical industry. With early drug discovery activities becoming increasingly significant in academia in recent years, Dr. Reichman's election will engender new opportunities in the field from a platform highly visible in both academia and industry. To learn more about the SBS, visit: